NYSE - Delayed Quote • USD
Abbott Laboratories (ABT)
At close: 4:00 PM EDT
After hours: 4:52 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 22 | 22 |
| Avg. Estimate | 1.1 | 1.2 | 4.63 | 5.14 |
| Low Estimate | 1.09 | 1.17 | 4.57 | 5.03 |
| High Estimate | 1.12 | 1.23 | 4.7 | 5.44 |
| Year Ago EPS | 1.08 | 1.14 | 4.44 | 4.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 21 | 21 |
| Avg. Estimate | 10.37B | 10.56B | 41.74B | 44.77B |
| Low Estimate | 10.24B | 10.48B | 41.44B | 44.28B |
| High Estimate | 10.54B | 10.66B | 42.39B | 45.37B |
| Year Ago Sales | 9.7B | -- | 40.11B | 41.74B |
| Sales Growth (year/est) | 6.90% | -- | 4.10% | 7.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.05 | 1.1 | 1.19 | 0.95 |
| EPS Actual | 1.08 | 1.14 | 1.19 | 0.98 |
| Difference | 0.03 | 0.04 | 0 | 0.03 |
| Surprise % | 2.90% | 3.60% | 0.00% | 3.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.1 | 1.2 | 4.63 | 5.14 |
| 7 Days Ago | 1.11 | 1.2 | 4.6 | 5.09 |
| 30 Days Ago | 1.12 | 1.21 | 4.6 | 5.09 |
| 60 Days Ago | 1.12 | 1.21 | 4.59 | 5.11 |
| 90 Days Ago | 1.12 | 1.2 | 4.63 | 5.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 3 | 3 |
| Up Last 30 Days | 4 | 5 | 13 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 2 | 4 |
Growth Estimates
| CURRENCY IN USD | ABT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 1.90% | -- | -- | 6.50% |
| Next Qtr. | 5.30% | -- | -- | 12.00% |
| Current Year | 4.30% | -- | -- | 5.30% |
| Next Year | 11.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 8.10% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 9.85% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 4/22/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 4/18/2024 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 4/4/2024 |
| Maintains | Citigroup: Buy to Buy | 4/3/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/14/2024 |
| Maintains | Barclays: Overweight to Overweight | 1/26/2024 |
Related Tickers
MDT Medtronic plc
79.74
+0.62%
BSX Boston Scientific Corporation
73.17
-0.12%
DXCM DexCom, Inc.
124.34
-9.91%
SYK Stryker Corporation
335.61
-0.46%
EW Edwards Lifesciences Corporation
86.43
-1.80%
ALGN Align Technology, Inc.
309.02
-0.48%
PODD Insulet Corporation
166.19
+1.23%
ZBH Zimmer Biomet Holdings, Inc.
119.35
-0.33%
INMD InMode Ltd.
17.14
+0.71%
SWAV Shockwave Medical, Inc.
330.00
+0.31%